Last reviewed · How we verify
MEZLOCILLIN SODIUM
At a glance
| Generic name | MEZLOCILLIN SODIUM |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1981 |
Approved indications
Common side effects
Key clinical trials
- Mood and Cognitive Effects of Psilocybin in Healthy Participants (EARLY_PHASE1)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEZLOCILLIN SODIUM CI brief — competitive landscape report
- MEZLOCILLIN SODIUM updates RSS · CI watch RSS